iPSC C1-15
NUIGi055-A
General
Cell Line |
|
| hPSCreg name | NUIGi055-A |
| Cite as: | NUIGi055-A (RRID:CVCL_A4DC) |
| Alternative name(s) |
iPSC C1-15
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
NUIGi055-B (iPSC C1-16) NUIGi055-C (iPSC C1-17) |
| Last update | 5th January 2021 |
| User feedback | |
Provider |
|
| Generator | National University of Ireland Galway (NUIG) |
| Owner | National University of Ireland Galway (NUIG) |
| Distributors | |
| Derivation country | Ireland |
External Databases |
|
| BioSamples | SAMEA7601555 |
| Cellosaurus | CVCL_A4DC |
| Wikidata | Q105510458 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA7601556 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Clinical Research Ethics Committee, Merlin Park Hospital, Galway, Ireland |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | Clinical Research Ethics Committee, Merlin Park Hospital, Galway, Ireland |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Clinical Research Ethics Committee, Merlin Park Hospital, Galway, Ireland |
| Approval number | C.A. 750 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Clinical Research Ethics Committee, Merlin Park Hospital, Galway, Ireland |
| Approval number | C.A. 750 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell line name | SAMEA7601555 |
| Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
Yes |
| Absence of reprogramming vector(s)? |
Yes |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
| Vector map | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | clones were randomly selected for characterization. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Gentle Cell Dissociation Reagent
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™ Flex
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
Embryoid body formation assay was performed to examine the functional pluripotency of iPSC C1-15. Alpha-smooth muscle (ASM) actin was used as the marker of mesoderm; nestin was used for detection of neuroectoderm; alpha-fetoprotein (AFP) was applied for targeting endoderm lineages.
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| Alpha Fetoprotein |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.